

euroPLX



Business Developer

Vol. 11 # 10 | October | 2015

Featured Vacancies in Business
Development and Licensing

Alkermes Inc.: Manager, Business Development, based in Waltham, MA, U.S.A. (<http://www.alkermes.com>)

Amdipharm Mercury Company Limited: Business Development Analyst - BDA, based in unspecified location, India (<http://www.amcolimited.com>)

Aspira Scientific Inc: Business Development Manager, based in Milpitas, CA, U.S.A. (<http://aspirasci.com>)

Asterand, Inc.: Director of Business Development- Life Sciences, based in North West US, U.S.A. (<http://www.asterand.com>)

Becton Dickinson & Co.: MBA Business Development Internship, based in Franklin Lakes, NJ, U.S.A. (<http://www.bd.com>)

Boehringer Ingelheim: Senior Strategic Portfolio Manager, based in Shanghai, China, People's Rep. (<http://www.boehringer-ingelheim.com>)

Boehringer Ingelheim: Business Development & Key Account Manager, based in Vienna, Austria (<http://www.boehringer-ingelheim.com>)

Catalent Pharma Solutions, Inc.: Business Development Manager, based in unspecified location, U.S.A. (<http://www.catalent.com>)

Trans-Pacific Partnership Does Not Please All

The Trans-Pacific Partnership agreement has provoked a lot of controversy. While many fear that US jobs may emigrate, the pharmaceutical industry has its own concerns.

The Trans-Pacific Partnership (TPP) which is designed to eliminate a number of trade barriers between the USA, Canada, and Mexico on the American, and 9 countries on the Asian and Oceanian side does not make everybody happy. The Partnership was agreed on in early October and will be officially signed until the end of the year.

One of the pitfalls of TPP is the minimum period of protection to biologics. While US trade associations such as the Biotechnology Industry Organization (BIO) and the Pharmaceutical Research and Manufacturers of America (PhRMA) campaigned for 12 years of data protection to ensure there would be incentive for innovation, Australia and New Zealand had opted for five years, to allow greater patient access to cheaper, copycat biosimilars, and that is what the negotiating committee agreed on.

BIO said on 4 October, it „believes that 12 years of data exclusivity is a prerequisite to attract the investment required to continue medical innovation and develop new biological cures and therapies. The current 12-year period of exclusivity in the United States was carefully crafted by a bi-partisan majority of the Congress after a

thorough and thoughtful debate and deliberation. The Congress set 12 years as the appropriate period to both foster innovation and provide access to biosimilars in a reasonable timeframe. While the TPP agreement will not impact the U.S. data protection

period, we believe the failure of our Asian-Pacific partners to agree to a similar length of protection is remarkably short-sighted and has the potential to chill global investment and slow development of new breakthrough treatments for suffering patients.“

Complimentary Advertisement of a euroPLX 59 Athens Registrant



SIIT - Innovative Healthcare Products

- Development and manufacturing of Pharmaceutical, Medical Devices and Health Food Supplements (in GMP, ISO 22000) of Finished Products in solid & liquid dosage oral forms
- Siit has a complete pipeline of innovative consumer healthcare products ready to license out: Oropharyngeal care, gastrointestinal care, women's health, metabolic syndrome, baby & children's health, immune support. Please contact d.mazza@siit-it.com ...or discuss this opportunity with us at euroPLX 59 Athens!

Complimentary Advertisement of a euroPLX 59 Athens Registrant



The "Full Service" by Liberty Pharma

Liberty Pharma offers The Pharmaceutical Full Service compiling 3 complementary activities: Development and sourcing of API, Development of MA Dossiers and Manufacturing of the finished forms, especially in the C&C, mouthwash, laxative and antacid therapeutic areas. We also offer innovative herbal OTC products and food supplements. Please contact maxime.hassid@libertypharma.lu ...or discuss this opportunity with us at euroPLX 59 Athens!

Complimentary Advertisement of a euroPLX 59 Athens Registrant



HUONS Provides Total Health Care Products

Huons is a leading company in the life industry and has produced essential medicine. We have researched and developed pharmaceutical products constantly for last 48 years. Huons is specialized in the injection field and BFS line. With this strong point, we have occupied local market and exported to mainly USA, Japan, etc. We are doing aggressive marketing for overseas and make an effort for providing the medical solution for human health. Please contact intbiz@huons.com ...or discuss this opportunity with us at euroPLX 59 Athens!

Chiesi Farmaceutici SpA: Business Development & Licensing Manager, based in Parma, Italy (<http://www.chiesigroup.com>)

CMC Biologics A/S: Director, Business Development - East Coast, based in Bothell, WA, U.S.A. (<http://www.cmcbio.com>)

Collegium Pharmaceutical, Inc.: Manager, Business Development, based in Canton, MA, U.S.A. (<http://www.collegiumpharma.com>)

CoNCERT Pharmaceuticals Inc.: Senior Director, Business Development, based in Lexington, MA, U.S.A. (<http://www.concertpharma.com>)

Curis, Inc.: Manager, Business Development, based in Lexington, MA, U.S.A. (<http://www.curis.com>)

Dr. Kade Pharmazeutische Fabrik GmbH: Analyst Corporate Development (descr. in German), based in Berlin, Germany (<http://www.kade.de/en/>)

Dr. Kade Pharmazeutische Fabrik GmbH: Intern Corporate Development (descr. in German), based in Berlin, Germany (<http://www.kade.de/en/>)

Duchesnay Inc.: Director, Business Development, based in Blainville QC, Canada (<http://www.duchesnay.com>)

Duchesnay Inc.: Senior Manager, Business Development, based in Blainville QC, Canada (<http://www.duchesnay.com>)

Edwards Lifesciences Corp.: Senior Manager, Strategy & Business Development - Heart Valve Therapy, based in Irvine, CA, U.S.A. (<http://www.edwards.com>)

F. Hoffmann - La Roche Ltd.: Business Development & Access Manager, based in Santiago, Chile (<http://www.roche.com>)

F. Hoffmann - La Roche Ltd.:

Complimentary Advertisement of a euroPLX 59 Athens Registrant



Delorbis Pharmaceuticals Ltd

We are a leading branded generic company that offers a broad portfolio of high quality pharmaceutical products to millions of people all over the world. Our Contract Manufacturing allows small batch size production, fast delivery & flexibility when it comes to volume & scheduling. Learn more about what we can offer you at www.delorbispharma.eu because at DELORBIS it's not about us, it's about you. Because we care. Please contact delorbis@delorbispharma.eu ...or [discuss this opportunity with us at euroPLX 59 Athens!](#)

Complimentary Advertisement of a euroPLX 59 Athens Registrant



Generic Injectable Depot Products for License

Harvest Moon Pharmaceuticals, USA is developing generic octreotide LAR, risperidone depot, paliperidone palmitate, and lanreotide autogel depots in Europe and the USA. We plan our ANDA filings in the USA in 12/2016 and the DCPs in Europe in 2017. Limited territorial licenses are available. For a commercial quote, send a country (countries) forecast (s) and target supply price(s) (FOB USA or FOB Europe) to: rich.dicicco@harvestmoonpharma.com ...or [discuss this opportunity with us at euroPLX 59 Athens!](#)

Complimentary Advertisement of a euroPLX 59 Athens Registrant



We Provide Products Ready to Market!

For 20 years, Substipform has been providing quality products & services to quality partners! We invest in the development and manufacturing of our own products to offer you a wide range of pharmaceutical generic, OTC & niche products. We are by your side from the registration of the dossier to the supply of the finished product. Our team would be pleased to provide you with additional information. Please contact us at business@substipform.com ...or [discuss this opportunity with us at euroPLX 59 Athens!](#)

In a public statement of 5 October the PhRMA declared: „We are disappointed that the Ministers failed to secure 12 years of data protection for biologic medicines, which represent the next wave of innovation in our industry. This term was not a random number, but the result of a long debate in Congress, which determined that this period of time captured the appropriate balance that stimulated research but gave access to biosimilars in a timely manner.“

So what is behind the controversy concerning the length of data protection? If a biosimilar maker wants to file his own application with regulators, he must refer to the results of clinical trials of the biopharmaceutical conducted by the originator. The longer the data are protected, the longer a competitor is kept from launching a rival drug. With a longer period innovators derive higher economic benefits from an expensive original drug while a shorter period might decrease their interest

in innovating, given the smaller economic incentive.

Recent BD&L Management Changes

* Applied Genetic Technologies Corp: **Eric Olson**, who held multiple roles at Genzyme, has been appointed as Senior Director, Corporate Development. (Press Release 5 Oct 2015)

* BioBlast Pharma Ltd.: **Theresa Stevens** most recently, President and Chief Corporate Development Officer of Lupin, has been appointed to the newly-created position of Chief Corporate Development Officer. (Press Release 9 Oct 2015)

* Dr. Max Pharma Limited: **Ivan Berkes**, who has been the CEO of the company has sold his shares and resigned from his position. He will remain active as an advisor to the team for the next few months. (Pers Comm 5 Oct 2015)

* ELC Group s.r.o.: **Diego Ingrassia**, most recently with PH&T as

Licensing Manager Europe, has been appointed as Business Development & Licensing Senior Manager. (Pers Comm 28 Sep 2015)

* GeneriNobel GmbH: Dr. **Wolfgang Bäurle**, who has been Group Leader Generics at Wörwag Pharma, left the company in order to join GeneriNobel as Managing Director. He follows Dr. Rolf Tiggemann, who has retired, and represents the European outlicensing business of Turkish generic company Nobel Ilac. GeneriNobel is engaged in the development, manufacturing and outlicensing of pharmaceutical products (Rx and OTC) for all european markets. (Pers Comm 17 Oct 2015)

* Glenmark Pharmaceuticals Ltd.: **Martin Albert**, who has been Head of Business Development Europe, left the company. (Pers Comm 25 Sep 2015)

* HUYA Bioscience International: **Shawn Xiaojun Mu** Ph.D. has been appointed as Vice President of Business Development, China. (Press Release 8 Oct 2015)

* Oystershell NV: **André Janssens**, who has been Business Development Manager, retired. (Pers Comm 9 Sep 2015)

* PharOS Ltd.: **Christian Duchow**, who has been heading the day-to-day operations of PharOS and who continues to be one of the shareholders, stepped down in order to serve as Director of PharmSol, Dubai. (Pers Comm 25 Sep 2015)

* Synmosa Biopharma Corp.: **Ray Yang** who has previously been responsible for business development affairs at Standard Chem. & Pharm. has been appointed as Project Manager Business Development. (Pers Comm 19 Oct 2015)

Senior Business Development Manager, based in New York, NY, U.S.A. (<http://www.roche.com>)

F. Hoffmann - La Roche Ltd.: Director Business Development, based in Pleasanton, CA, U.S.A. (<http://www.roche.com>)

F. Hoffmann - La Roche Ltd.: Sr. Manager Business Development, Oncology, based in South San Francisco, CA, U.S.A. (<http://www.roche.com>)

F. Hoffmann - La Roche Ltd.: Global BD and M&A Manager, Roche Diagnostics, based in Basle, Switzerland (<http://www.roche.com>)

F. Hoffmann - La Roche Ltd.: Diagnostics / Pharma Partnering Director, Diagnostics Business Development, based in Basle, Switzerland (<http://www.roche.com>)

F. Hoffmann - La Roche Ltd.: Business Development Director - Research & Technologies Partnering, based in Basle, Switzerland (<http://www.roche.com>)

Fresenius AG: Director New Therapeutic Area & Business Development Mature & Emerging Markets, based in Oberursel, Germany (<http://www.fresenius-ag.com>)

GeneData AG: Business Development Manager, based in various locations, U.S.A. (<http://www.genedata.com>)

GeneData AG: Business Development Manager, based in Basle, Switzerland (<http://www.genedata.com>)

Genfit Corp.: VP Business Development, based in Boston, MA, U.S.A. (<http://www.genfit.com>)

Heumann Pharma: Licensing Manager, based in Nuremberg, Germany (<http://www.heumann.de>)

Company News: Mergers, Acquisitions

* Acquisition: **Alvogen** has acquired five hormonal branded products from **Bayer Pharma AG** in Russia and CIS. The products acquired are Klimonorm (Hormone replacement therapy), Progynova (Hormone replacement therapy), Triquilar (Female contraception) and Microgynon (Female contraception) and Climene (Hormone replacement therapy). 6 Oct 2015 (www.alvogen.com)

* Acquisition: **Amicus Therapeutics, Inc.** has successfully completed the acquisition of **Scioderm, Inc.** a privately-held biopharmaceutical company for approximately \$229 million. 30 Sep 2015 (www.amicustherapeutics.com)

* Distribution: **Apricus Biosciences, Inc.** has signed an exclusive distribution agreement with **Ferring Pharmaceuticals** to market Vitaros™ (alprostadil), its topical on-demand product for the treatment of erectile dysfunction, in Latin American countries. 1 Oct 2015 (www.apricusbio.com)

* Acquisition: **BioMarin Pharmaceutical Inc.** has re-acquired all global rights to Kuvan® (sapropterin dihydrochloride) and pegvaliase from **Merck Serono** (Merck) in a deal which could be worth US\$525 million. Pegvaliase is currently in registration-enabling pivotal studies as a potential therapeutic option for adult patients with phenylketonuria. 1 Oct 2015 (www.bmrn.com)

* Merger: **Biscayne Pharmaceuticals, Inc.** has merged with **Insero Health**, a developer of novel treatments for epilepsy, pain and other central nervous system (CNS) disorders. 5 Oct 2015 (biscaynepharma.com)

* Acquisition: **Cardinal Health** has completed the acquisition of **Johnson & Johnson's Cordis** busi-

ness, a global leader in cardiology and endovascular devices, for \$1.944 billion. 4 Oct 2015 (www.cardinalhealth.com/en.html)

* Co-Promotion: **Cardiome Pharma Corp.** has entered into a Co-Promotion Agreement with **Mitsubishi Tanabe Pharma Europe Ltd.**, a subsidiary of **Mitsubishi Tanabe Pharma Corporation** headquartered in Japan, to co-promote Cardiome's AGGRASTAT® (tirofiban HCL) and MTPE's EXEMBOL® (argatroban monohydrate) in the United Kingdom. Cardiome and MTPE will co-promote the two products thereby leveraging their existing sales forces and investments in this market for an initial term of 3 years. 30 Sep 2015 (www.cardiome.com)

* Partnership: **Cipla Ltd's** South African subsidiary **Cipla Medpro (Pty) Ltd.** has entered into an exclusive agreement with the world's largest vaccine manufacturer, **Serum Institute of India (SII)** in South Africa. The partnership is expected to not only enable

affordable and accessible vaccines for South Africans, but will also facilitate a reliable supply stream to the South African Government. SII manufactures a variety of vaccine classes including vaccines for Polio, Diphtheria, Tetanus, BCG (Tuberculosis), Hepatitis B, Measles, Mumps and Rubella; South Africa will be participating in the majority of these portfolios. 8 Oct 2015 (www.cipla.com)

* Marketing: **Cumberland Pharmaceuticals Inc.**, a specialty pharmaceutical company focused on hospital acute care and gastroenterology, has agreed to a strategic alliance with **Clinigen Group plc** to market, promote and distribute each other's portfolios in their home markets. 17 Sep 2015 (www.cumberlandpharma.com)

* Distribution: **Dompé farmaceutici** and **Omega Pharma**, a division of **Perrigo Company plc**, signed an agreement for the international marketing of the OTC product range of the Italian biopharmaceutical Group. Omega Pharma

Complimentary Advertisement of a euroPLX 59 Athens Registrant

Seid Labs: Magnesium

Seid S.A. is a family owned pharmaceutical lab based in Barcelona - Spain, mainly focused in woman's health area. We offer Licensing Out & supply agreements for our new Magnesium dossier, to partners interested in distributing our quality medicines & supplements in available territories, through long term collaborations. Other dossiers for LO and reliable Contract Manufacturing Services are also available. Please contact export@lab-seid.com ...or discuss this opportunity with us at euroPLX 59 Athens!

Complimentary Advertisement of a euroPLX 59 Athens Registrant

Intas New CTD Dossiers

Intas develops Dossiers approved worldwide with 10 manufacturing sites in India, México and UK. Vast portfolio of 100+products. Intas' CRO is biggest in Asia (Phase I-IV & BE). INTAS' Biotech got G-CSF approval in EU. Intas offers EU-test & release facilities in Barcelona. CTD Dossiers: BupropionSR; Simva+Eze; Sirolimus; Vardenafil; Disulfiram; Ivabradine; Dabigatran; Febuxostat; Aml+Olme; Lacosamide; Rivaroxaban; Agomelatin; Prasugrel. Please contact Intas3P@intaspharma.com ...or discuss this opportunity with us at euroPLX 59 Athens!

Complimentary Advertisement of a euroPLX 59 Athens Registrant

Venture Life Offers Women's Healthcare

vonalei™, an exciting new product range from Venture Life addresses the needs associated with women's health. The range includes topical medical devices for vaginal atrophy, BV and candidiasis, as well as a cosmetic cleansing foam, all of which help to promote good vaginal health. Please contact scollins@venture-life.com ...or discuss this opportunity with us at euroPLX 59 Athens!

Hovione: Business Development Manager, based in Lisboa, Portugal (<http://www.hovione.com>)

ICON Clinical Research, Inc.: Business Development Director, based in Seoul, Korea (<http://www.iconplc.com/>)

ICON Clinical Research, Inc.: Senior Director, Business Development (Scandinavia), based in Stockholm, Sweden (<http://www.iconplc.com/>)

ICON Clinical Research, Inc.: Business Development Director, based in Chicago, U.S.A. (<http://www.iconplc.com/>)

Lundbeck A/S: Manager, Business Development, Forecasting and Commercial Assessment, based in Deerfield, IL, U.S.A. (<http://www.lundbeck.com>)

Medimmune, Inc.: Director, Partnerships & Collaborations, based in Gaithersburg, MD, U.S.A. (<http://www.medimmune.com>)

MedMira Laboratories: Business Development and Sales Associate, based in Atlanta, GA, U.S.A. (<http://www.medmira.com>)

Mega Lifesciences Ltd.: Business Development Manager (descr. in Thai), based in Bangna, Bangkok, Thailand (<http://www.megawecare.com>)

Multipharma SA: Business Development Manager, based in Tokyo, Japan (<http://www.multipharma.ch>)

Novartis Pharma AG: Analyst, Strategy & Business Development, based in Boucherville, Canada (<http://www.novartis.com>)

Novartis Pharma AG: Executive Director, Business Development & Licensing, based in Princeton, NJ, U.S.A. (<http://www.novartis.com>)

Novartis Pharma AG: Business Intelligence and Development Analyst, based in Vilvoorde,

Complimentary Advertisement of a euroPLX 59Athens Registrant

Innovative Iron Deficiency Treatment Offered

BMG Pharma offers a range of innovative products for the treatment of all iron deficiency related anemias. IronOne is liposomal Iron available in softgel capsules in 3 presentations. It utilizes a unique liposomal coating technology to create a product which allows the molecule to pass through the stomach, avoiding gastrointestinal irritation, proving it extremely effective with published data in over 270 patients. Please contact paul.phull@bmgpharma.com ...or discuss this opportunity with us at euroPLX 59 Athens!

Complimentary Advertisement of a euroPLX 59Athens Registrant



Natrpharm: Unique Chance in the Philippines

As second largest national pharma company (ethical field) in the Philippines known for its high quality products and competent field force (500) is looking for a medical food with indications and clinical trials. Natrpharm's objective: to market pharmaceutical products in the Philippine territory through licensing and/or supply agreements with national and international companies by providing its partners with comprehensive, integrated service. Please contact thomashoegn@gmx.com ...or discuss this opportunity with us at euroPLX 59 Athens!

Complimentary Advertisement of a euroPLX 59Athens Registrant



New OTC Product by Abdi Ibrahim

Abdi Ibrahim, the leading Turkish Pharmaceutical company exporting to more than 50 countries globally now offers 600 mg Acetylcysteine+ 200 mg Vitamin C effervescent tablet combination in EU CTD format. The product with its unique selling point represents a big potential for the companies having a OTC focus & sales strategy. Limited number of licences will be given. Please contact cengiz.zaim@abdiibrahim.com. tr Export & Licensing Director ...or discuss this opportunity with us at euroPLX 59 Athens!

has been granted the exclusive right to distribute the main brands of the OTC line of the Italian group in over 50 countries. The first marketing activities are expected in 2017 and should cover key countries in Europe. 30 Sep 2015 (www.dompe.com)

* Acquisition: **Endo International plc** has completed its previously announced \$8.05 billion acquisition of **Par Pharmaceutical Holdings, Inc.** from leading global private investment firm TPG. (28 Sep 2015) Endo also completed a portfolio of branded and generic injectable and established products focused on pain, anti-infectives, cardiovascular and other specialty therapeutics areas from a subsidiary of Aspen Holdings. 1 Oct 2015 (www.endo.com)

* Acquisition: **Ethypharm** has acquired 100% of the share capital of **DBA Group (DB Ashbourne)**, a branded pharmaceutical business established in the UK in 2009. DBA currently markets and supplies a

range of prescription only medicines to the UK market. 1 Oct 2015 (www.ethypharm.com)

* Rights: **Ferring Pharmaceuticals** has acquired the global rights to MILPROSATM (progesterone vaginal ring) from **Teva Women's Health, Inc.** MILPROSA has the potential to be the first once-weekly progesterone treatment for luteal phase support in women undergoing Assisted Reproductive Technology (ART) treatment if approved by regulatory authorities in the United States. 28 Sep 2015 (www.ferring.com)

* Acquisition: **Hikma Pharmaceuticals PLC** has agreed to acquire 98.09% of the share capital of **EIMC United Pharmaceuticals** from a consortium of shareholders. EUP is a pharmaceutical manufacturing company specialising in oncology products. 8 Sep 2015 (www.hikma.com)

* Distribution: **IDT Australia Limited** has finalised an agree-

ment with a US subsidiary of **Mayne Pharma Group Limited** to distribute IDT's generic Temozolomide product in the United States of America. IDT filed an Abbreviated New Drug Application for Temozolomide in late 2013. Temozolomide is indicated for the treatment of melanoma and glioblastoma multiforme. 24 Sep 2015 (en.idtaus.com.au)

* Acquisition: **IDT Biologika** acquired **Gallant Custom Laboratories**, based in Ontario, Canada. Gallant Custom Laboratories is the only Canadian company authorized by the Canadian Food Inspection Agency to manufacture autogenous viral and bacterial vaccines. 25 Aug 2015 (www.idt-biologika.de)

* Acquisition: **Karo Bio** has acquired the shares in **Swereco Group** for a purchase price of 250 MSEK. The sum consists of a cash component of 118 MSEK and the remaining part of new shares. Swereco markets OTC products mainly to pharmacies or directly to health care providers. 2 Oct 2015 (www.karobio.se)

* Acquisition: **Mallinckrodt plc** has completed its acquisition of **Therakos, Inc.**, from **The Gores Group** at a purchase price of approximately \$1.325 billion. 28 Sep 2015 (www.mallinckrodt.com)

* Divestment: **Norgine B.V.** has completed its agreement with **Pharmacare Limited**, a wholly owned subsidiary of **Aspen Pharmacare Holdings** for the divestment of its Southern African operations and product rights. 30 Sep 2015 (www.norgine.com)

* **OBI Pharma, Inc.**, a biotech company, signed an agreement with **MSD**, through a subsidiary, transferring exclusive rights to develop and commercialise Dificid (fidaxomicin) in Taiwan. Dificid is an orally administered, narrow-spectrum, macrocyclic antibiotic with a novel mechanism of action approved in Taiwan for

Belgium (<http://www.novartis.com>)

Novartis Pharma AG: Business Development & Licensing Manager, based in Freiburg, Germany (<http://www.novartis.com>)

Novartis Pharma AG: Business Dev. and Portfolio Spec., based in Warsaw, Poland (<http://www.novartis.com>)

Novella Clinical: Director, Business Development- Germany/ Eastern Europe, based in unspecified location, Germany (<http://www.novellaclinical.com/>)

Oncodesign S.A.: Business Development Manager, based in Dijon, France (<http://www.oncodesign.com>)

Pacira Pharmaceuticals, Inc.: Director, Business Development, based in Parsippany, NJ, U.S.A. (<http://pacira.com>)

Panacea Biotech Ltd.: Sr. Manager/ AGM – Business Development – Contract Research (CRO), based in New Delhi, India (<http://www.panaceabiotech.com>)

Piramal Healthcare: Chief Manager – Business Development, based in Mumbai, India (<http://www.piramal.com>)

Purdue Pharma L.P.: Business Development Finance, based in Stamford, CT,, U.S.A. (<http://www.pharma.com>)

Remedica Ltd: Business Development Officer, based in Limassol, Cyprus (<http://www.remedica.eu>)

Riemser Arzneimittel AG: Senior Business Development Manager (descr. in German), based in Berlin, Germany (<http://www.riemser.de>)

Sanofi US: Area Business Development Manager, based in South-West, UK, UK (<http://www.sanofi.us>)

the treatment of CDAD in adults 18 years of age or older under the trade name Difucid. 6 Oct 2015 (www.obipharma.com)

* Acquisition: **Octapharma AG** invests €80 million to acquire an exclusive worldwide license to certain IP of **Glycotope's** recombinant technology and to become a minority shareholder of Glycotope GmbH Berlin. 7 Oct 2015 (www.octapharma.com)

* Acquisition: **Pfizer Inc.** has completed its acquisition of **Hospira** for US\$15 billion, Inc. (3 Sep 2015), and the acquisition of **GlaxoSmithKline's** quadrivalent meningococcal ACWY vaccines Nimenrix and Mencevax for \$130 million. 1 Oct 2015 (www.pfizer.com)

* Acquisition: **Raptor Pharmaceutical Corp.** has completed the acquisition of Quinsair™ (levofloxacin inhalation solution) from **Tripex Pharmaceuticals**. Quinsair is the first inhaled fluoroquinolone antibiotic approved in the European Union and in Canada for the management of chronic pulmonary infections due to *Pseudomonas aeruginosa* in adults with cystic fibrosis. Raptor paid Tripex approximately \$34.2 million in cash consideration. 5 Oct 2015 (www.raptorpharma.com)

* Acquisition: **St. Jude Medical, Inc.** has completed the previously announced acquisition of **Thoratec Corporation**, a worldwide leader in mechanical circulatory support (MCS) technology for the treatment of advanced heart failure (HF). The transaction is valued at approximately \$3.3 billion. 8 Oct 2015 (www.sjm.com)

* Settlement: **Sun Pharmaceutical Industries Ltd.** has announced that Ranbaxy Pharmaceuticals Inc., a wholly-owned subsidiary, along with its partners, **Cipher Pharmaceuticals Inc.** and **Galephar Pharmaceutical Research, Inc.** have entered into

Complimentary Advertisement of a euroPLX 59Athens Registrant

Dutasteride softgel & Dutasteride/Tamsulosin caps

PharmaMatch's latest dossier developments are: Dutasteride softgel capsule 0.5mg: DCP started in 2015/03 | Dutasteride/Tamsulosin softgel capsule 0.5mg/0.4mg: Dossier ready 2016Q3 | Olopatadine eye drops: DCP completed | Palonosetron injection 250mcg/5ml: Pending MA in Portugal for MRP use | Racecadotril capsule 100mg: Dossier ready 2016Q1 | Dossiers are linked to a supply agreement, but other business models can be discussed. Please contact Marcel@pharmamatch.nl ...or discuss this opportunity with us at euroPLX 59 Athens!

Complimentary Advertisement of a euroPLX 59Athens Registrant



Licensing-in Opportunities from Neogen

Neogen has finalized several dossiers (CTD) which might be the perfect opportunity for you: Tranexamic Acid 250, 500, 750 & 1000 mg tablets, Loperamide 2 mg Film-coated tablets and Hard capsules, Tramadol 50 & 100 mg Hard capsules. Neogen expects 7 new dossiers ready for licensing out in the coming 6 months. Please contact licensing@neogen.be ...or discuss this opportunity with us at euroPLX 59 Athens!

Complimentary Advertisement of a euroPLX 59 Athens Registrant



OTC Products for MA's in Poland

Pharmavit ApS is searching for OTC products for MA's in Poland. Buying dossiers (MA's / Co-development / Swap). Please contact Ronald.schmid@gmail.com ...or discuss this opportunity with us at euroPLX 59 Athens!

Special Advertisement of a euroPLX 59 Athens Registrant

Krebsallianz Needs Your Help!

The incidence of cancer in the developing world is greater than that of Aids, TB and Malaria altogether. Delivering medical donations since 2006 to the developing world; Moldova, Ghana, Dominican Republic and Honduras. With expertise **Krebsallianz** offers photos, testimonials and great PR opportunities. We accept chemotherapies or essential meds with an expiry over 6 months, please contact info@krebsallianz.de +493081486098 ...or discuss this topic with Thomas Högn, Natrapharm at euroPLX 59 Athens!

a Settlement Agreement with **Actavis Group** that dismisses the patent litigation suit relating to Actavis' Abbreviated New Drug Application for a generic version of Absorica® (isotretinoin capsules). 6 Oct 2015 (www.sun-pharma.com)

* Acquisition: **Teva Pharmaceutical Industries Ltd.** has entered into definitive agreements under which the Company will acquire **Representaciones e Investigaciones Médicas, S.A. de C.V.** (Rimsa), a leading pharmaceutical manufacturing and distribution company in Mexico, along with a portfolio of products and companies, intellectual property, assets and pharmaceutical patents in Latin America and Europe in a debt-free, cash free set of transactions, for an aggregate of \$2.3 bil-

lion. Through this acquisition, Teva will become a leading pharmaceutical company in Mexico. 1 Oct 2015 (www.tevapharm.com)

euroPLX Newcomers at euroPLX 59 Athens (1)

The following companies registered for euroPLX 59 Athens are newcomers to euroPLX, i.e. they have never had a delegate at a euroPLX Conference before:

Based in Vrillissia, a town close to Athens, **Benostan Health Products S.A.** (www.benostan.gr) focuses on the development and marketing of plant-derived therapeutic and cosmetic products, in particular derived from olive, thyme, hypericum, rosemary, sage and calendula among others, using a proprietary extraction and

Shire Pharmaceuticals Group plc:
Head of Business Development,
GI & Endocrinology (Senior
Director), based in Lexington, MA,
U.S.A. (<http://www.shire.com>)

Surya Pharmaceutical Ltd.: GM/
AGM/Executives - Business
Development, based in
Chandigarh, India (<http://www.suryapharma.com>)

Takeda Pharmaceuticals
North America, Inc.: Business
Development Manager - Mexico,
based in Mexico, Mexico (<http://www.takeda.us/>)

Takeda Pharmaceuticals North
America, Inc.: Director, PV
Business Development & Alliance
Management, based in Boston,
MA, U.S.A. (<http://www.takeda.us/>)

Unichem Laboratories Ltd.:
Manager Business Development
(Regional Manager), based in
Hyderabad, India (<http://www.unichemlabs.com>)

United Therapeutics Corp.: Senior
Associate, Business Development,
based in Research Triangle Park,
NC, U.S.A. (<http://www.unither.com>)

VirtualScopics, Inc.: Business
Development Executive, based in
Rochester, NY, U.S.A. (<http://www.virtualscopics.com>)

Walgreen Co.: Business
Development Manager (2 posi-
tions), based in Northbrook, IL,
U.S.A. (<http://www.walgreens.com>)

WuXi PharmaTech Co Ltd:
Director of Business Development
for Analytical Development &
Formulation Development, based
in unspecified location, U.S.A.
(<http://www.wuxiapptec.com>)

More BD&L vacancies in pharma
and biotech are regularly listed
on www.raucon.com

production process.

Headquartered in Tokyo, **CBC Corporation Limited** (www.global-cbc.com) is a manufacturer, a trading company, and a full range supplier of chemicals, synthetic resins, and pharmaceuticals to electronics components & devices, security devices, and more. For the pharmaceutical industry, CBC offers API/Intermediates, excipients, peptide nucleic acid, cosmetics, supplements, and medical devices.

Established in 1979 and with a workforce of circa 200 employees, **Custom Pharmaceuticals** (<http://custompharm.com>) is a developer and manufacturer of solid dose formulations, based in the UK. The company has the capabilities to develop generic and NCE molecules applying a range of solid dose delivery systems including functional coatings.

Cyprus based **Delorbis Pharmaceutical Ltd** (www.delorbispharma.eu) is a branded generic pharmaceutical company, offering a broad portfolio of more than 100 pharmaceutical products. The company has over 600 marketing authorisations in more than 35 markets worldwide.

G.C. Group Ltd. (www.gcgroup.co.il) is a small pharmaceutical R&D company engaged in development of variety of innovative and generic drug products of different types.

GxMed Healthcare (www.gxmed.com) is based in Denmark and Spain and offers full distribution service including tender submission, stock management, invoicing, RA, QPPV, release, etc. for the Nordic region and Spain, but also for the UK, the Netherlands and Germany.

Huons Co., Ltd. (www.huons.com) is a global company, based in the Republic of Korea and producing original and effective essential medicine and medical products

since over 50 years such as special medical products, well-being medical products, plastic container injection, local anaesthetics and medical devices.

Located in Vienna, Austria, **Marinomed Biotechnology GmbH** (www.marinomed.com) is an R&D based pharmaceutical company founded 2006. The focus of its product pipeline is an anti-viral OTC portfolio based on the patented active compound Carragelese, a sulphated galactose polymer of red seaweeds which targets a broad list of respiratory viruses.

Sama Pharmceutical Co., Ltd. is a Korean pharmaceutical company with own R&D and manufacturing facilities. The company is leading in respiratory, ENT, dermatology and pediatrics in terms of prescription numbers and market share in Korea.

Synmosa Biopharma Corp. is a specialty pharmaceutical company based in Taipei, Taiwan, and active in R&D and manufacturing products in the fields of hormone replacement treatment, cardiovascular, neurology, respiratory, urology, hormonal oncology, oral contraceptives, and OTC.

With 1,110 employees, Athens based **VIANEX S.A.** (www.vianex.gr) is a leading pharmaceutical company in Greece with 90 years of experience in manufacturing, licensing, marketing, exporting and distribution of pharmaceutical products.